Autolus Therapeutics (AUTL) Capital Expenditures (2018 - 2025)

Autolus Therapeutics (AUTL) has reported Capital Expenditures for 8 consecutive years, with -$885000.0 the latest figure, recorded in Q4 2025.

• Quarterly Capital Expenditures fell 107.96% year-over-year to -$885000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19.0 million (down 13.73% YoY) and the FY2025 annual result came in at $19.0 million, down 13.73% from the prior year.
• Capital Expenditures slipped to -$885000.0 in Q4 2025 per AUTL's latest filing, from $4.4 million in the prior quarter.
• Over the last five years, Capital Expenditures for AUTL reached as high as $11.1 million in Q4 2024 and fell as low as -$885000.0 in Q4 2025.
• A 5-year average of $3.6 million and a median of $2.8 million in 2021 frame the typical range for Capital Expenditures.
• The largest YoY upside for Capital Expenditures was 1385.23% in 2025 against a maximum downside of 107.96% in 2025.
• Year by year, Capital Expenditures stood at $1.6 million in 2021, then tumbled by 60.06% to $633000.0 in 2022, then soared by 133.33% to $1.5 million in 2023, then surged by 652.34% to $11.1 million in 2024, then slumped by 107.96% to -$885000.0 in 2025.
• According to Business Quant data, Capital Expenditures over the past three periods registered -$885000.0, $4.4 million, and $7.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.